Azulfidine



Indications and Reactions:

Role Indications Reactions
Primary
Rheumatoid Arthritis 63.9%
Hypertension 6.1%
Gastritis 3.3%
Colitis Ulcerative 3.1%
Osteoporosis 2.6%
Gastric Ulcer 2.4%
Diabetes Mellitus 2.1%
Crohn's Disease 1.7%
Musculoskeletal Pain 1.7%
Pain 1.5%
Prophylaxis Against Gastrointestinal Ulcer 1.4%
Seronegative Arthritis 1.3%
Arthralgia 1.2%
Atrial Fibrillation 1.2%
Psoriatic Arthropathy 1.2%
Angina Pectoris 1.1%
Hyperlipidaemia 1.1%
Prophylaxis 1.1%
Arthritis 1.0%
Cardiac Failure Chronic 1.0%
Pyrexia 10.5%
Interstitial Lung Disease 9.0%
Drug Rash With Eosinophilia And Systemic Symptoms 6.6%
White Blood Cell Count Decreased 6.6%
Liver Disorder 5.9%
Rash 5.9%
Pancytopenia 5.5%
Stomatitis 4.7%
Drug Eruption 4.3%
Pneumonia 4.3%
Vomiting 4.3%
Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis 3.9%
Hepatic Function Abnormal 3.9%
Sepsis 3.9%
Weight Decreased 3.9%
Hypersensitivity 3.5%
Pleural Effusion 3.5%
Rheumatoid Arthritis 3.5%
Glomerulonephritis Membranous 3.1%
Septic Shock 3.1%
Secondary
Rheumatoid Arthritis 54.1%
Drug Use For Unknown Indication 7.4%
Product Used For Unknown Indication 6.6%
Hypertension 5.6%
Ankylosing Spondylitis 3.0%
Spondylitis 2.4%
Crohn's Disease 2.3%
Asthma 2.1%
Pain 2.0%
Osteoporosis 1.7%
Prophylaxis 1.7%
Seronegative Arthritis 1.7%
Gastritis 1.6%
Sjogren's Syndrome 1.6%
Colitis Ulcerative 1.5%
Gastric Ulcer 1.5%
Psoriatic Arthropathy 1.0%
Arthralgia 0.8%
Colitis 0.7%
Hyperlipidaemia 0.7%
Rheumatoid Arthritis 10.8%
Pyrexia 8.6%
Rash 7.2%
Pericardial Effusion 6.5%
Pneumonia 6.5%
Toxic Skin Eruption 5.8%
Liver Disorder 5.0%
Sepsis 5.0%
White Blood Cell Count Decreased 5.0%
Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis 4.3%
Generalised Erythema 4.3%
Interstitial Lung Disease 4.3%
Pleural Effusion 4.3%
Agranulocytosis 3.6%
Drug Hypersensitivity 3.6%
Pulmonary Tuberculosis 3.6%
Gastric Ulcer Haemorrhage 2.9%
Hepatic Function Abnormal 2.9%
Herpes Zoster 2.9%
Organising Pneumonia 2.9%
Concomitant
Rheumatoid Arthritis 47.3%
Product Used For Unknown Indication 18.0%
Hypertension 4.4%
Prophylaxis 3.8%
Crohn's Disease 3.2%
Drug Use For Unknown Indication 3.2%
Osteoporosis 3.1%
Psoriatic Arthropathy 3.0%
Ankylosing Spondylitis 2.1%
Colitis Ulcerative 1.6%
Pain 1.5%
Arthritis 1.2%
Gastritis 1.1%
Gastrooesophageal Reflux Disease 1.1%
Rhinitis Allergic 1.0%
Hyperlipidaemia 1.0%
Insomnia 1.0%
Depression 1.0%
Blood Cholesterol Increased 0.8%
Constipation 0.7%
Pneumonia 8.9%
Rheumatoid Arthritis 8.5%
Vomiting 8.1%
Interstitial Lung Disease 7.4%
Drug Ineffective 5.6%
Nausea 5.6%
Pneumocystis Jiroveci Pneumonia 5.2%
Injection Site Pain 4.8%
Weight Decreased 4.8%
Respiratory Failure 4.4%
Urinary Tract Infection 4.4%
Death 4.1%
Hepatic Function Abnormal 4.1%
Cerebral Infarction 3.7%
Pyrexia 3.7%
Sepsis 3.7%
Pain 3.3%
Skin Ulcer 3.3%
Tuberculous Pleurisy 3.3%
Palpitations 3.0%
Interacting
Rheumatoid Arthritis 37.5%
Hyperlipidaemia 12.5%
Hypertension 12.5%
Hypothyroidism 12.5%
Pain 12.5%
Pulmonary Embolism 12.5%
Drug Interaction 50.0%
Gastrointestinal Haemorrhage 50.0%